| Autor: |
Nathaniel B. Rex, Johanna M. Ospel, Rosalie V. McDonough, Nima Kashani, Leon A. Rinkel, Brian H. Buck, Jeremy Rempel, Ryan A. McTaggart, Raul G. Nogueira, Alexandre Y. Poppe, Dar Dowlatshahi, Brian A. van Adel, Richard H. Swartz, Ruchir A. Shah, Eric Sauvageau, Andrew M. Demchuk, Michael Tymianski, Michael D. Hill, Mayank Goyal |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Stroke: Vascular and Interventional Neurology, Vol 4, Iss 2 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2694-5746 |
| DOI: |
10.1161/SVIN.123.001034 |
| Popis: |
Background Nerinetide treatment was associated with better clinical outcomes among patients with stroke undergoing endovascular treatment who were not treated with concurrent alteplase in the randomized ESCAPE‐NA1 (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke) trial. In patients receiving alteplase, no such effect was seen due to an inactivation of nerinetide by plasmin – the product of tissue plasminogen activation. We hypothesized that improved outcomes in the no‐alteplase patients were associated with reduced infarct growth, a radiological correlate of improved stroke outcomes. Methods Data are from the no‐alteplase stratum of the ESCAPE‐NA1 trial. Patients who underwent computer tomography perfusion (CTP) as part of routine clinical care were included. Admission CTP source data were processed using RAPID software. Infarct core at baseline was defined as areas of relative cerebral blood flow |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text